Anakinra for patients with COVID-19

COVID-19 is caused by SARS-CoV-2, which originated in Wuhan, Hubei province, Central China, in December 2019 and since then has spread rapidly, resulting in a severe pandemic. The infected patient presents with varying non-specific symptoms requiring an accurate and rapid diagnostic tool to detect SARS-CoV-2. This is followed by effective patient isolation and early treatment initiation ranging from supportive therapy to specific drugs such as corticosteroids, antiviral agents, antibiotics, and the recently introduced convalescent plasma. The development of an efficient vaccine has been an on-going challenge by various nations and research companies. A literature search was conducted in early December 2020 in all the major databases such as Medline/PubMed, Web of Science, Scopus and Google Scholar search engines. The findings are discussed in three main thematic areas namely diagnostic approaches, therapeutic options, and potential vaccines in various phases of development. Therefore, an effective and economical vaccine remains the only retort to combat COVID-19 successfully to save millions of lives during this pandemic. However, there is a great scope for further research in discovering cost-effective and safer therapeutics, vaccines and strategies to ensure equitable access to COVID-19 prevention and treatment services.

show abstract

“…Ruxolitinib and anakinra are the other immunomodulatory drugs used in the on-going clinical trials for treating COVID-19 patients [52] , [53] .…”

Section: Resultsmentioning

confidence: 99%

A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19

Umakanthan

Chattu

Ranade³

et al. 2021

AIMS Public Health

View full text Add to dashboard Cite

show abstract

“…Merging various treatment options such as low-dose systematic corticosteroids and anti-viral drugs have been utilized for COVID-19 [64]. Several other treatment methods are also reported, including hydroxychloroquine [65], tocilizumab [66], convalescent plasma (immunotherapy) [67], and favipiravir (RdRp inhibitor) [68], remdesivir [69], anakinra [70], and dexamethasone [71] etc.…”

Section: Lack Of Vaccination and Definitive Treatmentmentioning

confidence: 99%

“…patients [70]. Studies have shown promising results upon treating severely affected patients with these IL-receptor antagonists.…”

Section: Use Of Monoclonal Antibodies and Therapeutic Proteinmentioning

confidence: 99%

Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease

Bhagat

Yadav

Shah

et al. 2020

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: In December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak occurred and caused the coronavirus disease of 2019 (COVID-19), which affected ~ 190 countries. The World Health Organization (WHO) has declared COVID-19 a pandemic on 11 th March 2020. Area covered: In the review, a comprehensive analysis of the recent developments of the COVID-19 pandemic has been provided, including the structural characterization of the virus, the current worldwide status of the disease, various detection strategies, drugs recommended for the effective treatment, and progress of vaccine development programs by different countries. This report was constructed by following a systematic literature search of bibliographic databases of published reports of relevance until 1 st September 2020. Expert opinion: Currently, the countries are opening businesses despite a spike in the number of COVID-19 cases. The pharmaceutical industries are developing clinical diagnostic kits, medicines, and vaccines. They target different approaches, including repurposing the already approved diagnosis and treatment options for similar CoVs. At present, over ~200 vaccine candidates are being developed against COVID-19. Future research may unravel the genetic variations or polymorphisms that dictate these differences in susceptibilities to the disease.

show abstract

Anakinra for patients with COVID-19

Cited by 2 publications

References 5 publications

A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19

A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19

Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease

Contact Info

Product

Resources

About